Newmed Energ Pu (DKDRF) AI Stock Analysis

Newmed Energ Pu

(Other OTC:DKDRF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Production and Revenue ExpansionHigher production across Israel, Egypt, and Jordan, combined with stronger realized prices, demonstrates improving asset utilization and regional demand. Sustained volume growth can support recurring revenue and operating leverage as infrastructure expands.

Negative Factors

Sharp Free Cash Flow DeteriorationWeak cash conversion means reported profitability is not translating efficiently into discretionary cash. Higher working capital, taxes, interest, or sustaining capital needs could constrain debt reduction, distributions, and funding for major projects.

Newmed Energ Pu (DKDRF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $18.98B
Dividend Yield: 4.04%
Average Volume (3M): 1,830
Price to Earnings (P/E): 24.2
Beta (1Y): 0.31
Revenue Growth: -6.17%
EPS Growth: -44.82%
Country: US
Employees: 24
Sector: General
Sector Strength: 55
Industry: Oil & Gas Exploration & Production

Newmed Energ Pu Business Overview & Revenue Model

Company Description

NewMed Energy - Limited Partnership is an energy firm engaged in the exploration, development, production, and commercialization of petroleum, natural gas, and condensate, primarily operating in Israel and Cyprus. The company holds significant intere...

Newmed Energ Pu Earnings Call Summary

Earnings Call Date:Aug 05, 2026(Q2-2026)|% Change Since:-1.25%|Next Earnings Date:May 25, 2024

Earnings Call SentimentPositive

The call presented multiple strong operational and financial improvements: production increased ~35%, revenues rose ~53% and net income ~44%, supported by higher gas prices and completed midstream works. Material infrastructure milestones (third pipeline, Ashdod–Ashkelon looping) and progress on major growth projects (Leviathan expansion on schedule, Aphrodite progressing toward FID) provide clear upside. Offsetting considerations include rising operating costs (+$21M), higher finance expenses (+$26M), net debt of ~$1.4B with an upcoming bond maturity in 2027, and some benefits that are timing‑lagged or accrue to partners rather than immediately to NewMed. Overall, positive momentum and meaningful value catalysts outweigh the noted financial and timing challenges.

Positive Updates

Strong Production Growth

Q2 2026 production of ~2.7 Bcm vs 2.0 Bcm in Q2 2025, an increase of ~0.7 Bcm (+35%). All three markets (Israel, Egypt, Jordan) grew, with Egyptian volumes increasing by ~0.5 Bcm in the quarter.

Negative Updates

Rising Operating Costs and Depreciation

Costs and expenses increased by ~$21M year‑over‑year, mainly from higher operations costs and depreciation, partially offsetting revenue gains.

Company Guidance

Management guided that Q2‑2026 results included production of 2.7 Bcm (vs. 2.0 Bcm in Q2‑2025, with ~+0.5 Bcm to Egypt), revenues of $293M (vs. $191M), net profit of ~$117–118M, average gas price $6.5/MMBtu (vs. $5.6), and a $60M dividend; net revenues rose ~$86M (≈$59M from higher production, $25M from higher price, $2.1M condensate) partially offset by ~$21M higher costs and ~$26M higher finance expenses, plus $6.8M other revenues and $7.7M discontinued‑operation income. Liquidity/financial guidance: net debt ≈$1.4B, $550M available bank facilities, ~$95M of bond buybacks to date, next bond maturity June‑2027. Capex/project guidance: third pipeline lifts peak capacity to 15.8 Bcm/year (from ~14.5, +1 Bcm), Ashdod–Ashkelon looping adds ~2 Bcm/year (allocated to Leviathan partners), Leviathan Phase‑1b on track for H2‑2029 with total cost ~$2.4B and ~23% complete and a rig to drill 3 wells by year‑end; FAJR+compression due EOY, Nitzana ahead of Phase‑2, Aphrodite FID targeted H1‑2027, and upcoming seismic surveys including a ~5,000‑node OBN survey.

Newmed Energ Pu Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

DKDRF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IL:DLEKG	63Neutral	ILS 15.05B	4.42	4.49%	0.07%	-43.39%	268.02%
IL:TOEN	63Neutral	ILS 269.01M	14.64	―	37.26%	-1.64%	9.82%
IL:TMRP	61Neutral	ILS 2.13B	15.77	―	15.30%	-15.98%	-22.66%
IL:NVPT	59Neutral	ILS 14.97B	15.28	―	3.25%	920.97%	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

DKDRF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DKDRF	Newmed Energy Limited Partnership	5.28	0.12	2.29%
IL:DLEKG	Delek Group	8288.00	280.82	3.51%
IL:ISRA	Isramco Negev 2 LP	220.40	-12.78	-5.48%
IL:TOEN	Tomer Energy Royalties (2012) Ltd.	1345.00	-487.88	-26.62%
IL:TMRP	Tamar Petroleum Ltd.	2665.00	-951.42	-26.31%
IL:NVPT	Navitas Petroleum LP	12130.00	1016.44	9.15%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Newmed Energ Pu AI Stock Analysis